MedTrace Logo

Duration of Medication Therapy and Outcomes After Holmium Laser Prostate Surgery for Patients With Benign Prostatic Hyperplasia (BPH)

NCT03768765 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 144

Last updated 2024-10-02

No results posted yet for this study

Summary

To determine if the prior prolonged use of medication, as a treatment for benign prostatic hyperplasia, reduces the efficacy of Holmium laser enucleation of the prostate (HoLEP) for patients with benign prostatic hyperplasia (BPH).

Conditions

  • Benign Prostatic Hyperplasia

Interventions

PROCEDURE

Holmium Laser Prostate Surgery

Patients will undergo standard of care holmium laser prostate surgery

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-15
Primary Completion
2024-06-19
Completion
2024-08-27

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03768765 on ClinicalTrials.gov